🔗 Share this article

As the United States continues making historic adjustments to its vaccine schedules, a particular individual has surfaced in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by expressing skepticism about coronavirus shots in the pandemic and has concentrated on potential deaths following Covid vaccination in her brief tenure at the US Food and Drug Administration (FDA).

Proposed Changes to Pediatric Immunization Program

Health officials planned to announce radical revisions to the childhood vaccination calendar in December, bringing the US with Denmark’s vaccine program, sources say – a significant shift that would put the US out of step with a large portion of the global community with no evidence for benefit. This reveal has been delayed until the new year.

In place of the director of the vaccine center, Tracy Beth Høeg is listed to address the audience at the meeting. She was just designated temporary leader of the FDA’s CDER, the fifth appointee to lead the division this calendar year.

A Shift at the Agency

Høeg's temporary position may indicate a strengthened alliance between the pharmaceutical and biologics branches as Høeg and Prasad strengthen their influence at the FDA – and it signals a renewed priority upon dismantling already-approved vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing specific pediatric immunization guidelines in the US in order to be more similar to the Danish model, a society with nationalized medicine and a number of inhabitants about the population of Wisconsin’s.

To date statements, she has continued to focus on vaccination policy – traditionally the domain of Prasad, director of the FDA’s CBER – rather than pharmaceutical oversight.

Questions Over Qualifications

Høeg has no obvious experience in pharmaceutical research, approval processes or administrative roles, which has been standard for former heads of the Center for Biologics Evaluation and Research. She has served at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the requisite experience” for overseeing the CDER, said Dr. Jonathan Howard. “She has not conducted a clinical trial. She is not versed in managing a major agency. She lacks background in industry regulation.”

Former directors of the center would “be deeply familiar with regulatory frameworks and the underlying principles of drug development”, commented Dr. Janet Woodcock. “Frankly, she has not acquired the sort of resume that former directors who led CBER have had.”

This division has an immense range of responsibilities at the agency, she emphasized.

“Many people just pays attention on the new drug program, but the off-patent medication office authorizes numerous generic drugs. There is also a biosimilars program, over-the-counter program and more, and all of those have to be managed,” she explained. “The thing you don’t keep your eye on, that is precisely what that I always told people is going to cause problems.”

There is also, a major administrative aspect to the position, which manages in excess of 5,000 employees. “It is a enormous management job, if you do it right,” the former official added.

Official Statement and Contentious Policies

When asked about inquiries about Dr. Høeg's qualifications and whether this selection represents greater collaboration among regulatory chiefs on vaccines, a spokesperson stated that the “concerns are based on inaccurate assumptions”.

“Her experience matches the duties of her job,” the official stated, pointing to the months Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including predictive safety algorithms and vaccine surveillance”.

As acting director, Høeg assumes responsibility for the commissioner’s recently launched priority voucher program, a contentious rapid drug-approval program that allegedly worried her former heads. “How are these therapies being chosen for this expedited pathway? Who makes the calls?” Howard said. “There’s a lot of confidentiality going on at the FDA right now.”

Overall, he said, “the FDA seems to be moving towards laxer oversight of pharmaceuticals, except for vaccines.”

Public Past Work on Vaccines

Concerning immunizations, Dr. Høeg has a more established, if problematic, track record, Howard said. She published a analysis using non-validated volunteer-provided data to assess the frequency of heart inflammation after Covid vaccination. She counseled the state of Florida chief medical officer Dr. Joseph Ladapo, who was said to have altered data to imply Covid vaccines are pose a greater threat than they are.

Among her “wish list” for the incoming administration encompassed revising regulations for recently developed shots and halting “non-essential” vaccines, she remarked following the vote on a audio program. At the FDA, Dr. Høeg has allegedly floated the idea of preventing adolescent males from receiving COVID-19 vaccinations.

“She’s an thorough ideologue who commences with her beliefs and tailors the evidence to fit the science in a very misleading, fraudulent fashion,” Howard said.

Taking Control and a “Revenge Tour”

Høeg became part of other contrarians, {like|